EA201001270A1 - Новый способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac) - Google Patents

Новый способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac)

Info

Publication number
EA201001270A1
EA201001270A1 EA201001270A EA201001270A EA201001270A1 EA 201001270 A1 EA201001270 A1 EA 201001270A1 EA 201001270 A EA201001270 A EA 201001270A EA 201001270 A EA201001270 A EA 201001270A EA 201001270 A1 EA201001270 A1 EA 201001270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulphonyplyroles
histondezetylase
hdac
inhibitors
obtaining
Prior art date
Application number
EA201001270A
Other languages
English (en)
Other versions
EA017929B1 (ru
Inventor
Маттиас МЮЛЛЕР
Бернд МЮЛЛЕР
Томас Майер
Original Assignee
4Сц Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Сц Аг filed Critical 4Сц Аг
Publication of EA201001270A1 publication Critical patent/EA201001270A1/ru
Publication of EA017929B1 publication Critical patent/EA017929B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Abstract

Способ получения соединения формулы (I), где R1, R2, R3, R4, R5 и R6 имеют значения, которые определены в описании, включающий стадию взаимодействия хлорангидрида акриловой кислоты формулы (II'), где R1, R2, R3, R4, R5 и R6 имеют значения, которые определены в описании, с водным гидроксиламином и, возможно, превращения полученного соединения в его соль присоединения кислоты.
EA201001270A 2008-03-12 2009-03-11 Способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac) EA017929B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004567A EP2100878A1 (en) 2008-03-12 2008-03-12 Novel method for the production of sulphonylpyrroles as HDAC inhibitors
PCT/EP2009/052870 WO2009112529A1 (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors

Publications (2)

Publication Number Publication Date
EA201001270A1 true EA201001270A1 (ru) 2011-04-29
EA017929B1 EA017929B1 (ru) 2013-04-30

Family

ID=39639400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001270A EA017929B1 (ru) 2008-03-12 2009-03-11 Способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac)

Country Status (23)

Country Link
US (1) US8785659B2 (ru)
EP (2) EP2100878A1 (ru)
JP (1) JP5530939B2 (ru)
KR (1) KR101571915B1 (ru)
CN (1) CN101970404B (ru)
AT (1) ATE519739T1 (ru)
AU (1) AU2009224623C1 (ru)
BR (1) BRPI0909752B8 (ru)
CA (1) CA2719074C (ru)
CY (1) CY1111994T1 (ru)
DK (1) DK2265580T3 (ru)
EA (1) EA017929B1 (ru)
ES (1) ES2370592T3 (ru)
HK (1) HK1150319A1 (ru)
IL (1) IL207995A (ru)
MX (1) MX2010010015A (ru)
NZ (1) NZ587824A (ru)
PL (1) PL2265580T3 (ru)
PT (1) PT2265580E (ru)
SI (1) SI2265580T1 (ru)
UA (1) UA102091C2 (ru)
WO (1) WO2009112529A1 (ru)
ZA (1) ZA201006422B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
KR20180130565A (ko) 2016-04-14 2018-12-07 4에스체 악티엔게젤샤프트 아시아 환자에서의 레스미노스타트의 의학적 적용
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
DK0570594T3 (ru) * 1991-12-10 1997-08-25 Shionogi & Co
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
JP4856623B2 (ja) 2004-03-11 2012-01-18 フォーエスシー アクチエンゲゼルシャフト 新規のｎ−スルホニルピロール誘導体
EP1861365B1 (en) * 2005-03-15 2009-07-01 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US8188138B2 (en) 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
SI1928872T1 (sl) 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC

Also Published As

Publication number Publication date
SI2265580T1 (sl) 2011-12-30
MX2010010015A (es) 2011-04-05
CA2719074A1 (en) 2009-09-17
US20110105568A1 (en) 2011-05-05
BRPI0909752B8 (pt) 2021-05-25
ES2370592T3 (es) 2011-12-20
UA102091C2 (ru) 2013-06-10
DK2265580T3 (da) 2011-10-31
ATE519739T1 (de) 2011-08-15
NZ587824A (en) 2012-05-25
CA2719074C (en) 2017-01-17
CY1111994T1 (el) 2015-11-04
ZA201006422B (en) 2011-10-26
EP2100878A1 (en) 2009-09-16
IL207995A (en) 2013-04-30
AU2009224623C1 (en) 2014-01-23
EP2265580B1 (en) 2011-08-10
BRPI0909752B1 (pt) 2020-11-24
PL2265580T3 (pl) 2012-01-31
PT2265580E (pt) 2011-11-21
IL207995A0 (en) 2010-12-30
CN101970404A (zh) 2011-02-09
JP5530939B2 (ja) 2014-06-25
US8785659B2 (en) 2014-07-22
KR101571915B1 (ko) 2015-11-25
EA017929B1 (ru) 2013-04-30
JP2011513467A (ja) 2011-04-28
EP2265580A1 (en) 2010-12-29
KR20100121656A (ko) 2010-11-18
WO2009112529A1 (en) 2009-09-17
AU2009224623A1 (en) 2009-09-17
CN101970404B (zh) 2013-05-08
BRPI0909752A2 (pt) 2015-10-06
HK1150319A1 (en) 2011-11-25
AU2009224623B2 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
EP2662352A3 (en) Method for Producing Phenylacetamide Compound
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
MX2010001773A (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxasol .
RU2012103850A (ru) Би-арил-мета-пиримидиновые ингибиторы киназ
MX2014006992A (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
TW200745027A (en) Novel sulphonylpyrroles
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
MX340125B (es) 2-hidroxi-4-(metiltio) butironitrilo estable en almacenamiento.
GB0412769D0 (en) Organic compounds
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
TW200612959A (en) Method for preparing hydroxamic acids
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
EA201001270A1 (ru) Новый способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac)
MX2011007006A (es) Sal doble de acido de cefdinir y su preparacion.
MX2014003638A (es) Cristal de hidrato 5-hidroxi-1h-imidazol-4-carboxamida-3/4, metodo para producir el mismo y cristal de hidrato de 5-hidroxi-1h-imidazol-4-carboxamida.
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
JO3189B1 (ar) طريقة جديدة لتخليق (e2) -3- (3, 4- داي ميثوكسي فينيل)بروب-2 - يننيتريل واستخدامها لتخليق ايفابرادين والاملاح المضافة منها مع حمض مقبول صيدلانيا
AR082593A1 (es) Proceso para la preparacion de pirazoles
EA200702350A1 (ru) Анилиды тиазолкарбоновой кислоты
EP1985313A4 (en) POSITRON TOMOGRAPHY METHOD AND POSITRON TRANSMITTER COMPOUND FOR USE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM